Dr. Peter Black of the Vancouver Prostate Centre on former President Joe Biden's cancer diagnosis
15 hours ago
Duration 5:09
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on September 15, 2025, to stockholders of record as of the close of business on September 1, 2025. About Premier, Inc. Premier, Inc. (NASDAQ: PINC) is a leading technology-driven healthcare improvement company, providing solutions to two-thirds of all healthcare providers in the U.S. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers and payers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, consulting and other services in service of our mission to improve the health of communities. Please visit Premier's news and investor sites on as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier's blog for more information about the company.
National Post
an hour ago
- National Post
Cohesys Announces First-in-Human Use of Investigational BoneTape™ in Craniofacial Fracture Repair
Article content TORONTO — Cohesys Inc., a Toronto-based medical device developer of resorbable fixation technologies, today announced that the first participants have undergone treatment with BoneTape™, an investigational device designed for the fixation of non-load-bearing craniofacial fractures. The procedures were completed as planned and mark the first clinical use of this drill- and screw-free fixation system. Article content 'Reaching this milestone is significant for Cohesys as we evaluate BoneTape's potential to offer a simpler, patient-friendly approach to fracture repair,' said Dr. Michael Floros, CEO of Cohesys. 'The data from this study will inform our regulatory strategy and commercialization pathway.' Article content 'This marks an exciting step forward for the study, and it's a privilege to be part of an effort exploring new techniques in facial-fracture treatment,' said Dr. Jeffrey A. Fialkov, MD, MSc, FRCSC, Head of the Division of Plastic and Reconstructive Surgery at Sunnybrook Health Sciences Centre, Associate Professor in the Department of Surgery at the University of Toronto, and Principal Investigator for the study. 'BoneTape's hardware-free approach is intended to simplify surgery and may improve the recovery experience for patients.' Article content Device- and procedure-related risks—including infection, non-union, and re-operation—will be actively monitored throughout the study's follow-up period. Article content Dr. Janaina Bortolatto, VP, Clinical Operations for Cohesys noted, 'The completion of these first cases with BoneTape reflects the dedication of our team and our clinical partners. We are focused on gathering the clinical data needed to evaluate BoneTape for potential future use.' Article content BoneTape is applied with a handheld applicator that affixes the resorbable fixation device to bone surfaces without drilling or screws. The study will determine whether this design performs as intended, potentially sparing patients from device-related complications and the need for hardware-removal procedures. Article content Cohesys Inc. develops advanced resorbable fixation solutions aimed at simplifying surgery and improving bone healing. BoneTape, the company's primary technology, is currently under clinical investigation. For more information, visit Article content . BoneTape™ is a trademark of Cohesys Inc. Article content Regulatory Status Article content Article content Article content
CTV News
2 hours ago
- CTV News
Doctors are seeing more non-smokers, especially women, with later-stage lung cancer
Katie Hulan, 37, is one of a growing number of non-smoking women doctors are seeing who have lung cancer. Hulan is seen in an undated handout photo. THE CANADIAN PRESS/Handout - Mohammed Asaduallah (Mandatory Credit) TORONTO — Katie Hulan's family doctor thought she might have asthma. Her cough, which had started about a month and a half earlier, was getting progressively worse. So he gave her some puffers to try, but they didn't work. 'I was just getting to the point where I couldn't speak at work,' said the 37-year-old tech marketing manager. 'At the end of the day, I would be in pain just from the shaking and coughing.' Her doctor ordered an X-ray that showed a mass on her lung. '(My doctor) said to go to emergency, thinking it was a blood clot,' Hulan remembers. After about six hours of more tests, they told her she had stage 4 lung cancer. 'That was one of the most devastating moments of my life,' she said. 'My immediate reaction was, 'I know how this story ends.' And so for me, it just felt completely like a death sentence.' She had been healthy, active and didn't smoke. 'For me to get a cancer diagnosis was a big shock. And then to have a lung cancer diagnosis was very puzzling for me,' said Hulan, who was diagnosed in Toronto in late 2020 and has since moved to Victoria where she continues treatment. She's one of a growing number of non-smokers doctors are seeing with lung cancer. Although smoking remains the leading risk factor, the Canadian Cancer Society estimates about a quarter of lung cancer cases in the country are non-smokers. In addition, more of those non-smokers are women than men and it's not clear why, said Jessica Moffatt, vice-president of programs and advocacy at the Lung Health Foundation. 'One of the theories is that potentially estrogen is doing something to perpetuate tumour growth, but it's all theories at this point,' she said. What scientists do know is that environmental factors contribute to lung cancer risk, especially radon gas. According to Health Canada, long-term exposure to radon — an invisible, radioactive gas from the breakdown of uranium in soil and rocks — is the number one cause of lung cancer among non-smokers. The agency says radon is present to some degree in every home and urges everyone to get a radon test kit to check their levels. Other risk factors include exposure to second-hand smoke, asbestos and the fine particulate matter in air pollution, Moffatt said. As wildfires rage across the country, the effects of that smoke is 'a huge concern for us' and is an area being studied to determine lung cancer risk, she said. Dr. Rosalyn Juergens, a medical oncologist at McMaster University and Hamilton Health Sciences Centre, said studies have shown that people living in areas with high air pollution rates have a higher risk of developing lung cancer. Over about 20 years in practice, she has 'absolutely' seen a rise in non-smoking lung cancer patients. 'It was uncommon for me, not never, but uncommon for me, to see a never-smoker when I first started in practice. And we are definitely seeing more and more,' said Juergens, who is also the president of Lung Cancer Canada. It's not clear whether there are more non-smokers getting lung cancer or if they just make up a greater proportion of the patients as fewer people smoke than ever before, she said. Many of her non-smoking patients are women, but people simply aren't aware of lung cancer as a women's health issue, she said. When non-smokers reach her office, their cancer is often in advanced stages. 'More women will die of lung cancer than will die of breast cancer, ovarian cancer, and cervical cancer combined,' Juergens said. 'One in five of them will be people who have never touched a cigarette a day in their lives.' Although organized lung cancer screening programs have been running in British Columbia, Ontario and Nova Scotia since 2022, they only target smokers, so non-smokers don't get the benefit of that early detection. In addition, lung cancer is often not top-of-mind for primary-care providers when non-smoking patients come in with a cough, Juergens said. 'The tricky part about lung cancer is symptoms are generally very subtle, right? Your lungs inside don't have nerve endings. So it's not like you're going to get a pain. You're never going to feel a lump,' she said. But the good news for many patients, Juergens said, is that lung cancer treatment has advanced dramatically since the 1990s, when chemotherapy was often the only option. 'We do things called next generation sequencing on the vast majority of lung cancers, and that helps us to sort what exact type of lung cancer it is and pick the right treatments,' she said. That precision medicine turned Katie Hulan's initial life expectancy of six months into an average of five to six years. A biopsy showed that her cancer had an ALK genetic mutation — one of about a dozen biomarkers that have specific medications to target the cancerous cells, and is only present in about four per cent of cases. 'When I got that news, it felt like a 180. I had life. I had hope. You know, my oncologist sat down and said, 'you won the lottery, you have years,'' she said. Almost five years after her diagnosis, Hulan continues to take a pill as her treatment, never had to undergo chemotherapy, feels 'wonderful' and is determined to live a long, full life. She now does advocacy work for the Lung Health Foundation to call for equal access to targeted cancer medication across the country and to urge people to seek medical attention if they have a cough that lasts more than two or three weeks. 'I think the word on the street is that you have to be a person who has smoked and that's not at all the case,' she said. 'Anyone with lungs can get lung cancer.' This report by The Canadian Press was first published Aug. 18, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Nicole Ireland, The Canadian Press
